Lung Cancer Dispatch
4.7K views | +0 today
Follow
Lung Cancer Dispatch
News for Patients and Physicians
Curated by Cancer Commons
Your new post is loading...
Your new post is loading...
Suggested by Cancer Commons
Scoop.it!

Rash from Tarceva May Herald Drug Effectiveness

Rash from Tarceva May Herald Drug Effectiveness | Lung Cancer Dispatch | Scoop.it

Skin rash is a common side effect of the lung cancer drug erlotinib (Tarceva). However, a clinical trial suggests that this rash can be a good sign and can be used to guide dosing. One hundred twenty-four patients with advanced non-small cell lung cancer (NSCLC) received first-line treatment with Tarceva. The drug dose was gradually increased until patients developed a skin rash or other side effects that prevented further dose increases. Seventy percent of patients developed a skin rash. Patients who developed a skin rash survived longer than those who did not (6.8 months longer on average), even though they did not differ in how much the treatment reduced the growth of their tumors.

Cancer Commons's insight:

News-Medical.Net  |  Dec 16, 2013

more...
No comment yet.
Rescooped by Cancer Commons from Melanoma Dispatch
Scoop.it!

New Software Quickly Maps Tumors for Radiotherapy

New Software Quickly Maps Tumors for Radiotherapy | Lung Cancer Dispatch | Scoop.it

To help protect healthy tissues from the radioactive drugs that target tumors, oncologists laboriously map the tumors by hand from sections of three-dimensional (3-D) images. But now researchers have developed a faster way. Based on computed tomography (CT) imaging data from a patient, 3-D graphic design software creates a model of the tumor in just an hour or two. When combined with a test that simulates the fate of therapeutic radioactivity in the body, the tumor model also lets oncologists personalize the radiotherapy dose. A study of several patients showed that this fast, new method maps organs and radiotherapy doses as accurately as conventional methods. The new software is expected to be used in a clinical trial of a tumor-targeted radiotherapy; a commercial version is scheduled for release to other cancer centers next year.

Cancer Commons's insight:

Medical Xpress│Jun 11, 2013

more...
Cancer Commons's curator insight, June 11, 2013 5:42 PM

Medical Xpress│June 11, 2013

Cancer Commons's curator insight, June 12, 2013 1:05 PM

Medical Xpress│June 11, 2013

Cancer Commons's curator insight, June 12, 2013 1:05 PM

Medical Xpress│June 11, 2013